Abstract:As the sentinels of the immune system, dendritic cells (DCs) play a critical role in initiating and regulating antigen-specific immune responses. Cross-priming, a process that DCs activate CD8 T cells by cross-presenting exogenous antigens onto their MHCI (Major Histocompatibility Complex class I), plays a critical role in mediating CD8 T cell immunity as well as tolerance. Current DC vaccines have remained largely unsuccessful despite their ability to potentiate both effector and memory CD8 T cell responses. There are two major hurdles for the success of DC-based vaccines: tumor-mediated immunosuppression and the functional limitation of the commonly used monocyte-derived dendritic cells (MoDCs). Due to their resistance to tumor-mediated suppression as inert vesicles, DC-derived exosomes (DCexos) have garnered much interest as cell-free therapeutic agents. However, current DCexo clinical trials have shown limited clinical benefits and failed to generate antigen-specific T cell responses. Another exciting development is the use of naturally circulating DCs instead of in vitro cultured DCs, as clinical trials with both human blood cDC2s (type 2 conventional DCs) and plasmacytoid DCs (pDCs) have shown promising results. pDC vaccines were particularly encouraging, especially in light of promising data from a recent clinical trial using a human pDC cell line, despite pDCs being considered tolerogenic and playing a suppressive role in tumors. However, how pDCs generate anti-tumor CD8 T cell immunity remains poorly understood, thus hindering their clinical advance. Using a pDC-targeted vaccine model, we have recently reported that while pDC-targeted vaccines led to strong cross-priming and durable CD8 T cell immunity, cross-presenting pDCs required cDCs to achieve cross-priming in vivo by transferring antigens to cDCs. Antigen transfer from pDCs to bystander cDCs was mediated by pDC-derived exosomes (pDCexos), which similarly required cDCs for cross-priming of antigen-specific CD8 T cells. pDCexos thus represent a new addition in our arsenal of DC-based cancer vaccines that would potentially combine the advantage of pDCs and DCexos.

Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy

When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

Biomimetic Dendritic Cell-Based Nanovaccines for Reprogramming the Immune Microenvironment to Boost Tumor Immunotherapy

Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy

Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy

Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance

Quantum Dot-Pulsed Dendritic Cell Vaccines Plus Macrophage Polarization for Amplified Cancer Immunotherapy.

Biomimetic and bioinspired nano‐platforms for cancer vaccine development

Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines

Nanobiomaterial-based vaccination immunotherapy of cancer

A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy

Engineering ApoE3-incorporated Biomimetic Nanoparticle for Efficient Vaccine Delivery to Dendritic Cells Via Macropinocytosis to Enhance Cancer Immunotherapy

DC-Based Vaccines for Cancer Immunotherapy

Engineering Nanoparticles toward the Modulation of Emerging Cancer Immunotherapy

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Hybrid Cell Membrane-Camouflaged Nanoparticle: A Novel Multifunctional Biomimetic Drug Delivery Carrier for Cancer Therapy

Engineering Energy‐Responsive Magnetic Nanomaterials to Improve the Efficacy of Dendritic Cell‐Based Immunotherapy

The role of dendritic cells in cancer immunity and therapeutic strategies

Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.